News
The drug is under distribution and will be in pharmacies by end of the month, said Vikrant Shrotriya, Novo Nordisk's India ...
In a statement, Novo Nordisk said that it was terminating the collaboration "due to concerns about their illegal mass ...
The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...
The drug works by acting on key areas of the brain involved in appetite regulation and food intake thereby reducing hunger, ...
Novo Nordisk said Hims & Hers has "failed to adhere to the law which prohibits mass sales of compounded drugs" under the ...
14h
Novo Nordisk ends Wegovy sales on Hims & Hers over "deceptive marketing" Novo Nordisk said it will stop selling Wegovy on ...
Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.
Hims & Hers Health stock plunged after Novo Nordisk (NYSE: NVO) cut ties over concerns about its handling of Wegovy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback